Gómez-Pue D, Ibarrola-BuenAbad E, Lara-Núñez D, Vázquez-Alvarado AP, Pérez-Quintanilla M

Language: Spanish
References: 18
Page: 614-619
PDF size: 323.58 Kb.

ABSTRACT

Background: Over the last decade, evidence suggests the fallopian tubes are the origin of most of the high grade ovarian serous carcinomas. This type of carcinoma represents at least 50% of all the cases of epithelial ovarian cancer. Salpingectomy may lower the risk of high grade serous carcinoma. Removing the two fallopian tubes should be considered a strategy for risk reduction in patients who decide tubal sterilization or in patients with hysterectomy for benign disease. There are ongoing protocols that evaluate the ovarian hormonal production impact after prophilactic salpingectomy. In patients with BRCA1 and BRCA2 mutations, salpingo-oophorectomy is recommended usually between 35 to 40 years of age for BRCA 1 and between 40 and 45 years of age for BRCA 2. The oopherectomy done whithin these decades has the consequences and side effects of premature menopause, some physicians have suggested doing a two step procedure: perform a salpingectomy as soon as the patient has decided to have permanent birth control, and doing the ophoorectomy at the onset of menopause. The oncological safety of this approach is still under evaluation and is not recommended outside a protocol.

REFERENCES

1. Foulkes WD. Preventing ovarian cancer by salpingectomy. Curr Oncol 2013;20(3):139-42.

2. Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology 2014;65(2):149-54. Available from: http://www.ncbi.nlm. nih.gov/pubmed/24660659

3. Chene G, Rahimi K, Mes-Masson A-M, Provencher D. Surgical implications of the potential new tubal pathway for ovarian carcinogenesis. J Minim Invasive Gynecol 2013;20(2):153-9. Available from: http://www.ncbi.nlm. nih.gov/pubmed/23332575

4. Committee on Gynecologic Practice. Committee opinion no. 620: Salpingectomy for ovarian cancer prevention. Obstet Gynecol 2015;125(1):279-81. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/25560145

5. Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: Primum non nocere. Gynecol Oncol 2013;129(3):448-51. Available from: http:// linkinghub.elsevier.com/retrieve/pii/S0090825813001789

6. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - Shifting the paradigm. Hum Pathol 2011;42(7):918-31. Available from: http://dx.doi.org/10.1016/j.humpath.2011.03.003

7. Kuhn E, Meeker A, Wang T-L, Sehdev AS, Kurman RJ, Shih I-M. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010;34(6):829-36. Available from: http://content.wkhealth.com/linkback/openurl?sid =WKPTLP:landingpage&an=00000478-201006000-00010

8. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31(2):161-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17255760

9. Przybycin CG, Kurman RJ, Ronnett BM, Shih I-M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34(10):1407-16. Available from: http://content.wkhealth.com/linkback/openurl?sid =WKPTLP:landingpage&an=00000478-201010000-00002

10. Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer 2013;23(9):1603-11. Available from: http://www.ncbi.nlm. nih.gov/pubmed/24172097

11. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211(1):26-35. Available from: http://www.ncbi.nlm. nih.gov/pubmed/17117391

12. Mingels MJJM, Roelofsen T, van der Laak JAWM, de Hullu JA, van Ham MAPC, Massuger LFAG, et al. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol 2012;127(1):88-93. Available from: http://linkinghub. elsevier.com/retrieve/pii/S0090825812004532

13. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Front Oncol 2014;4:21. Available from: http://journal.frontiersin.org/article/10.3389/ fonc.2014.00021/abstract

14. Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJE. Support of the “fallopian tube hypothesis” in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2013;49(1):132-41. Available from: http://linkinghub.elsevier.com/retrieve/ pii/S0959804912006041

15. Swanson CL, Bakkum-Gamez JN. Options in prophylactic surgery to prevent ovarian cancer in high-risk women: how new hypotheses of Fallopian tube origin influence recommendations. Curr Treat Options Oncol 2016;17(5):20. Available from: http://link.springer.com/10.1007/s11864- 016-0396-2

16. Narod SA. Salpingectomy to prevent ovarian cancer. Curr Oncol 2013;20(3):145-7.

17. Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol [Internet]. 2013 Jan;121(1):14–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 23232752

18. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol [Internet]. 2014 May;133(2):283–6. Available from: http://www.ncbi.nlm. nih.gov/pubmed/24582866.